Danielle Wallace

@Matt_Cortese @RoswellPark IITs are a labor of love! Congrats Matt

Proud to open my 1st IIT clinical trial, hoping to advance the SOC for #RichterTransformation #DLBCL type from #CLL / #SLL using a chemo-free approach, with the first ncBTKi + PD1i/CPI combo for this challenging disease. clinicaltrials.gov/study/NCT06863… #lymsm #leuksm @RoswellPark

Sun Sets on R-Gem/Ox as Bispecific Antibodies Rise: Our thoughts on the SUNMO Trial. These results support the use of mosun/pola in patients ineligible or post CAR-T, and mosun/pola should replace R-Gem/Ox in future trials. @JCO_ASCO @WilmotCancer ascopubs.org/doi/10.1200/JC…

Wilmot Cancer Institute is officially a National Cancer Institute-Designated Cancer Center! This puts us in the nation’s top 4% of cancer centers. #WeareNCIDesignated @theNCI

How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma ow.ly/GCWG50UGYSl #HowITreat #lymphoidneoplasia

@majorajay @heMEGirl_MD crushed it!

BsAbs after CAR relapse #ASH24 - 830 pts! - mPFS 145 d, mOS 227 d - PD w/i 90 days: mOS 150 d - however, if relapse >90 d: mOS 3 yrs! Really great to see that outcomes can be good for late post-CAR relapse. #lymsm #tcellrx

Amazing collaborations in this successful @theNCI study led by Dr. Herrera. @SWOG @eaonc @COGorg @CDNCancerTrials @ALLIANCE_org Inclusive study enrolling pts aged 12+ with remarkable efficacy across all analyzed subgroups. Best-ever reported US results. nejm.org/doi/full/10.10…

Proud of this paper with my fantastic mentor @DrCarlaCasulo and geriatric oncology expert @MelissaLoh21 👵🚗👴🧬

@dgermain21 😬 you think they would try to be competitive or at least in reasonable range with the other NYS “thruway” programs…

Change comes from trainee solidarity, like this. And we (including recent trainees) should all be more transparent about our benefits to help others advocate. Considering cost of living, makes no sense UB pays 10% less than WashU.

@Eddie_Cliff And FEELING it melt away often after 1 cycle. “Lymphoma privilege”

This is one of the best things about treating lymphoma - watching it melt away

Upstate NY Cancer Symposium Day 2: - Hodgkin’s lymphoma w/ @alexniu25 - Non-Hodgkin’s lymphoma w/ @DWallaceMD - CLL w/ @Matt_Cortese @RoswellPark @WilmotCancer #lymsm #HemeTwitter

Recommending Treatment for Patients With Relapsed DLBCL After CAR T-Cell Therapy : collaboration with @DWallaceMD in @ASCOPost dailynews.ascopubs.org/do/recommendin…

@taylorcoxmd @joebeigemd @amyblattMD @KingMazumdarMD @vpulous @ericamillermd The hematology version of this is “IDA” for years despite iron, and von Willebrand if they’ve never seen a hematologist (👀 at you OB pt is in active labor consults)

@majorajay Super helpful! This came up in clinic a few months ago and could not find anything published in OLT patients

Rituximab for EBV+ after solid organ tplant to prevent PTLD #ASH23: - 2168 pts (!!!), median time SOT➡️EBV+ 688d - 1.6% of pts who received R got PTLD - 10% of pts didn't get R got PTLD - OR 0.15 for PTLD in pts who got post-SOT R Huge cohort! #lymsm ash.confex.com/ash/2023/webpr…

Found some fellow med-ed nerds at the @ASH_hematology #ASHMEI! 🤓Great week of education and collaboration. Ready to get to work back home at @WilmotCancer with our fantastic @URMCInternalMed residents rotating on our malignant heme service!

@URMC_SHWIM @URMC_DeptMed @UR_Med @ASH_hematology @AMedina_Walpole @DrCarlaCasulo Thanks! It’s been a fun few months and so happy to be sticking around

Shout out to @DWallaceMD on finishing Heme/Onc fellowship, joining our @URMC_DeptMed faculty, receiving a @UR_Med Aging Institute Pilot Award, AND joining the @ASH_hematology Medical Educators Institute 🙌🏽🤩 @AMedina_Walpole @DrCarlaCasulo

Really proud of this one! Thank you so much for sharing, @drcbsteer !

I am incredibly proud to be part of this team. The majority of our cancer patients receive treatment in community settings. At Webster @WilmotCancer, we are dedicated to providing the finest care, close to home. Moreover, we are actively expanding the availability of clinical trials, ensuring swift access to cutting edge treatment for all our patients. @DrR_DUNNE @rochgerionc @oreganruth @ArpanAshokPatel @NimishMohile @DrJFriedberg @KaitlinKyi @DWallaceMD #Oncology #OncTwitter #Hematology #MedEd #MedTwitter @HemOncFellows

@cioronce @UCLAFSPH @UCLA @UCLA_GIMHSR @NinezPonce So impressive! Congrats!

1/ 🚨Life update: I finally graduated with my last terminal degree (Ph.D in Health Policy) 3 weeks ago from @UCLAFSPH and I’m thrilled to share that I’ll be staying @UCLA as an Assistant Professor in @UCLA_GIMHSR!!! #schoolspiritskit

@Eddie_Cliff @WilmotCancer So happy to have met a fellow jr lymphoma investigator by pure bus coincidence!

Has been great to meet Dr @DWallaceMD this week #17ICML - @WilmotCancer is lucky to keep her!

What a way to end fellowship! Proud to see our work with U2Ven in MCL displayed at #ICML17. Always appreciative of the mentorship from the @WilmotCancer lymphoma team and thrilled to be joining.